Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib as adjuvant therapy to TACE in unresectable HCC
NCT00908752Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of brivanib in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Jul 2009; status: completed.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00908752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908752.